November 2016

Anti-cancer drug, CB-839, in combination with everolimus, stops tumours growing in patients with advanced kidney cancer

Munich, Germany: The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer when it is used in combination with another anti-cancer drug, everolimus. Dr Funda Meric-Bernstam told the 28th EORTC-NCI-AACR [1] Symposium on Molecular […]